arrow
S

Shuiqing He

中山大学肿瘤防治中心
H指数:4
被引数:57

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integrated Multiomic Analysis Reveals an EBV‐Associated MIF–SPP1 + Macrophage Axis Linking Tumor Stemness and Immune Dysfunction in Nasopharyngeal Carcinoma

整合多组学分析揭示EBV相关MIF–SPP1 <sup>+</sup> 巨噬细胞轴连接鼻咽癌的肿瘤干性与免疫功能障碍

2026-10-310
OAAI
Efficacy and safety of liposomal irinotecan plus nimotuzumab in immune checkpoint inhibitor-refractory recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase II trial

脂质体伊立替康联合尼莫单抗在免疫检查点抑制剂耐药的复发或转移性鼻咽癌中的疗效与安全性:一项单臂、开放标签、II期临床试验

2026-08-310
OAAI
Efficacy of metastasis-directed therapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy and local regional radiotherapy: a multicenter retrospective study

转移灶导向疗法在初诊转移性鼻咽癌患者接受化疗-免疫疗法和局部区域放射治疗中的疗效:一项多中心回顾性研究

2025-12-020
OAAI
Efficacy of metastatic lesion radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving local regional radiotherapy and chemo-immunotherapy: a multicenter retrospective study

转移性病变放疗对接受局部区域放疗和化疗免疫治疗的原发性转移性鼻咽癌患者的疗效:一项多中心回顾性研究

2025-09-230
PRE
CNG (Collaborative Nasopharyngeal Carcinoma Group) stage: Improved prognostic stratification of nasopharyngeal carcinoma and association with Epstein-Barr virus DNA in the intensity-modulated radiation therapy era

CNG(协作鼻咽癌组)分期:IMRT时代鼻咽癌改善预后分层与EB病毒DNA的关系

2025-07-190
PRE
The efficacy of immunotherapy combined with capecitabine versus immunotherapy alone as maintenance therapy in patients with de novo metastatic nasopharyngeal carcinoma: a retrospective propensity score matching study

免疫疗法联合卡培他滨与免疫疗法单药作为维持治疗在原发转移性鼻咽癌患者中的疗效比较:一项回顾性倾向性评分匹配研究

2025-06-010
OA
Single-cell transcriptome analysis reveals evolving tumour microenvironment induced by immunochemotherapy in nasopharyngeal carcinoma

单细胞转录组分析揭示了鼻咽癌中免疫化学疗法诱导的不断变化的肿瘤微环境

2024-10-160
OAAI